The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas & metastases) within the liver.

Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography

Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

An estimated 75 patients (age 18 years of age or older) will be enrolled from the population of patients who present for ultrasound-guided radiofrequency ablation (RFA) of CT or MRI-confirmed multiple primary hepatocellular carcinoma (HCC) or metastatic carcinoma, with at least one of the tumors being ≤ 1.5 cm in diameter.

Inclusion Criteria:

• Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic) carcinoma of the liver who have been referred for ultrasound-guided radiofrequency ablation (RFA) treatment
• Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in diameter
• Patient is stable and is to be managed conservatively (i.e. non-surgically)
• 18 years of age or older
• Ability and willingness to provide written informed consent

Exclusion Criteria:

• Known or suspected cardiac shunt(s)
• Known sensitivity to octafluoropropane
• Pregnant or breastfeeding

15 min post injection

All-cause mortality and other (not including serious) adverse events were not collected/assessed